Biomarkers of internal dose can be more accurate and precise surrogates for carcinogen exposures than environmental measurements
per se (
1). Yet, because chemical carcinogens are usually reactive electrophiles with very short life spans
in vivo (
2) (e.g., alkylating and acylating agents, aldehydes, alkylnitrosamines, dialkylsulfates, oxiranes, quinones, reactive oxygen and nitrogen species), it is rarely possible to measure them in target tissues. This has motivated the use of adducts of these electrophiles with abundant blood proteins, particularly hemoglobin (Hb) and human serum albumin (HSA), as measures of carcinogen dose (
3,
4). Electrophiles enter the blood from absorption in the lungs or gut (e.g., inhalation of ethylene oxide) or, more typically, via metabolism of procarcinogens in the liver or other tissues (e.g., production of benzene oxide by Cytochrome P-450 metabolism of benzene). Once in the blood, electrophiles react at varying rates with all available nucleophiles to form adducts by numerous mechanisms (
5). Hemoglobin and HSA contain a myriad of nucleophilic sites, namely the free thiol groups of Cys, amine groups of His, Trp, Lys, as well as the
N-termini, hydroxyl groups of Ser and Tyr, and the carboxylic acid groups of Asp, Glu, and the
C-termini. Since protein adducts are not repaired and are much more abundant than DNA adducts in blood (one ml of blood contains about 150 mg Hb, 30 mg of HSA, and 0.003–0.008 mg of DNA) (
5), they are potentially more useful measures of internal dose than DNA adducts, which have paradoxically received far more attention in this regard. Indeed, the kinetics of production and elimination of Hb and HSA adducts are sufficiently simple to permit straightforward estimates of systemic doses of carcinogens over the mean residence time of these proteins (28 d for HSA and 63 d for Hb in humans) (
6–
8).
Levels of targeted Hb and/or HSA adducts have been investigated in human blood for several environmental toxicants that are either electrophilic carcinogens or their precursors, i.e., ethylene oxide, benzene, 1,3-butadiene, acrylamide, aflatoxin B1, a variety of aromatic amines, and polycyclic aromatic hydrocarbons [reviewed in (
5)]. However, the need to obtain venous blood samples has limited the utility of protein adducts (and other blood-based biomarkers) as measures of exposure in large epidemiology studies. This has motivated investigators to employ dried blood spots (DBS) that can be obtained by a simple skin prick as sources of blood biomarkers. Robert Guthrie first used DBS in the 1960s to screen newborn populations for hyper-phenylalanine associated with the genetic disease phenylketonuria (
9). Neonatal DBS offer valuable opportunities for investigating chemical exposures
in utero and their possible links to childhood cancers. Immunoassays have been applied to measure a variety of biomarkers in DBS from adult populations, e.g., folate (
10), transferrin receptor (
11,
12), immunoglobulin E (
13), Epstein-Barr virus antibodies (
14), leptin (
15), and C-reactive protein (
16). Thus, DBS can potentially be used in both prospective and retrospective studies to process large numbers of blood specimens from human subjects.
A single dried blood spot (DBS) contains about 50 μl of human blood (
10). Assuming a protein concentration of 192 mg/ml (
17), one DBS should contain about 9.6 mg of protein of which there should be about 7.7 mg of Hb (80% of total protein) and 1.2 mg HSA (12% of total protein). Since most current assays for protein adducts typically require between 1 and 10 mg of globin (from Hb) or HSA, a single DBS should contain sufficient quantities of these proteins to measure adducts. Here, we describe experiments to isolate Hb in high purity from a single DBS, to purify the resulting globin, and to measure cysteinyl adducts of benzene oxide (BO-Hb) in these proteins. We previously detected BO-Hb in globin isolated from conventional venous blood samples in both benzene-exposed and control subjects and showed that levels of BO-Hb increased with the level of benzene exposure (
18). Detection of BO-Hb in control subjects points to production of adducts from environmental exposures to benzene and/or dietary and endogenous sources of benzene oxide or other precursor molecules that produce the same adduct (
19). In the current study, we show that BO-Hb is present at comparable levels in adult globin, isolated either from DBS or from conventional red blood cells, and in globin obtained from neonatal DBS.